The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England
- 26 November 2012
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 30 (50), 7205-7213
- https://doi.org/10.1016/j.vaccine.2012.10.017
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Effect of Serotype on Focus and Mortality of Invasive Pneumococcal Disease: Coverage of Different Vaccines and Insight into Non-Vaccine SerotypesPLOS ONE, 2012
- Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and WalesPLOS ONE, 2012
- Use of pneumococcal polysaccharide vaccine in childrenCurrent Opinion in Infectious Diseases, 2012
- Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort studyThe Lancet Infectious Diseases, 2011
- 7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement?PLOS ONE, 2011
- Temporal Trends in Invasive Pneumococcal Disease and Pneumococcal Serotypes over 7 DecadesClinical Infectious Diseases, 2010
- The current burden of pneumococcal disease in England and WalesJournal of Infection, 2006
- Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and WalesVaccine, 2004
- Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate VaccineThe New England Journal of Medicine, 2003
- Cost-Effectiveness of the Pneumococcal Vaccine in the United States Navy and Marine CorpsClinical Infectious Diseases, 2000